News provided by Lotus Pharma

• Lotus’s Lenalidomide is among the first to market in Germany, France, Spain, Italy, Netherlands Austria, Belgium, Switzerland, Czech Republic, Denmark, Finland, Ireland, Portugal, and Sweden
• February 2022 launch follows previous wave of first to market launches in 2019 in 10 countries in Central and Eastern Europe
• Lotus expects to launch Lenalidomide via partners as well as own commercial network in more than 90 countries around the globe by 2024
• Lotus is proud to deliver high quality drug more accessible to patients with haemato-oncology conditions around the world

Lotus Pharmaceutical (1795:TT), a multinational pharmaceutical company, today announced the successful launch of Lenalidomide Capsules (generic version of Revlimid®) in Germany, France, Spain, Italy, Netherlands Austria, Belgium, Switzerland, Czech Republic, Denmark, Finland, Ireland, , Portugal, and Sweden with a total market size of approximately US$2.8 billion for the past 12 months ended June 30, 2021 according to IQVIA data, under partner’s label via out-licensing model.

Lotus is planning to commercialize Lenalidomide directly or via licensees worldwide. Lotus Lenalidomide has been already launched in 39 countries and approved in 53 countries, including the tentative approval in the US since September 2020. It also has applications under registration in 30 countries and about to be submitted in 10 countries.  

Petar Vazharov, Chief Executive Officer of Lotus, said: “We are so proud that our leading oncology product, Lenalidomide, has achieved another major milestone with the second wave of first to market launches in the largest EU markets. Lenalidomide is the first oncology product fully developed and manufactured in our facilities in Taiwan, and it is also our first global product under roll-out in more than 90 countries. As a global leader in the development of oral oncology products, we are very pleased to expand access to our high-quality products to the patients worldwide. I would like to thank Lotus and Adalvo’s teams for the excellent collaboration and execution!”

Lenalidomide Capsules are indicated for the treatment of multiple myeloma. As disclosed by the originator, the total sales of Revlimid® globally were US$12.8 billion in 2021, including US$4.1 billion outside of the US.